Výsledky vyhledávání - "John H. Holcombe"

Efficacy and Safety of Insulin Lispro in Obese Patients with Type 2 Diabetes: A Retrospective Meta-Analysis of 7 Randomized Controlled Trials

Autor: Kim A. Gaskins, Tina M. Rees, Honghua H. Jiang, Justo Sierra-Johnson, Rong Liu, John H. Holcombe, Bradley H. Curtis

Publikováno v: Endocrine Practice. 20:389-398

To evaluate the efficacy and safety of insulin lispro in the treatment of patients with type 2 diabetes (T2DM) who had a body mass index (BMI) ≥30 kg/m2 (obese) compared with patients with BMIs30 kg/m2 (nonobese).A retrospective analysis of predefi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::125d2be39c01c228a5d2c72360638f8c
https://doi.org/10.4158/ep13301.or

Zobrazit plný text záznamu

Effect of exenatide on 24-hour blood glucose profile compared with placebo in patients with type 2 diabetes: A randomized, double-blind, two-arm, parallel-group, placebo-controlled, 2-week study

Autor: John H. Holcombe, Robert E. Ratner, Yongming Qu, Dennis Dong Hwan Kim, Sheila M. Lenox, Linda L. Fechner, Sherwyn Schwartz

Publikováno v: Clinical Therapeutics. 30:858-867

The aim of this study was to examine the glucose-lowering effect of exenatide over 24 hours in patients with type 2 diabetes with inadequate glycemic control using metformin, with or without a thiazolidinedione (TZD).This randomized, double-blind, 2-

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ace42a9448244c38f934510067c8dec6
https://doi.org/10.1016/j.clinthera.2008.05.004

Zobrazit plný text záznamu

Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years

Autor: Christopher L. Bowlus, Xuesong Guan, Matthew Wintle, David C. Klonoff, John B. Buse, David G. Maggs, John H. Holcombe, Loretta L. Nielsen

Publikováno v: Current Medical Research and Opinion. 24:275-286

Exenatide, an incretin mimetic for adjunctive treatment of type 2 diabetes (T2DM), reduced hemoglobin A(1c) (A1C) and weight in clinical trials. The objective of this study was to evaluate the effects ofor = 3 years exenatide therapy on glycemic cont

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::563eba6e43d57019d82655496311a2f8
https://doi.org/10.1185/030079907x253870

Zobrazit plný text záznamu

Sravnenie kombinatsiy insulina lizpromiks 25 s metforminom i insulina glarginas metforminom pri lechenii patsientovs sakharnym diabetom 2 tipa,ranee ne poluchavshikh insulinoterapii(16-nedel'noe randomizirovannoe otkrytoeperekrestnoe issledovanie)

Autor: L. E. Kerr, R. A. Sachson, John H. Holcombe, Barbara N. Campaigne, James Malone

Publikováno v: Сахарный диабет, Vol 9, Iss 2, Pp 41-49 (2006)

Цель. Оценка гликемического ответа при назначении лизпро микс 25 2 раза в сутки в комбинации с метформином по сравнению с терапией инсули�

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5cad91d844dad50ba16d5fdf41705dbb
https://doi.org/10.14341/2072-0351-6118

Zobrazit plný text záznamu

Management of type 2 diabetes: the role of incretin mimetics

Autor: John H. Holcombe, Dennis Kim, Anthony H. Stonehouse, David M. Kendall

Publikováno v: Drug Development Research. 67:545-552

Current strategies for the treatment of type 2 diabetes target deficient insulin secretion and insulin resistance, but have not been shown to correct the progressive β-cell dysfunction characteristic of the disease. Traditionally, type 2 diabetes is

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::9fd78c25b46c1e92984a6e177c6b1f09
https://doi.org/10.1002/ddr.20120

Zobrazit plný text záznamu

Exenatide elicits sustained glycaemic control and progressive reduction of body weight in patients with type 2 diabetes inadequately controlled by sulphonylureas with or without metformin

Autor: Susanna M. Mac, Robert R. Henry, Terri H. Poon, David G. Maggs, Bei Zhang, Dennis Kim, Matthew C. Riddle, John H. Holcombe

Publikováno v: Diabetes/Metabolism Research and Reviews. 22:483-491

BACKGROUND In two placebo-controlled 30-week trials, treatment with exenatide reduced HbA(1c) and body weight in patients with type 2 diabetes in the context of sulphonylurea (SU) or SU plus metformin (MET) as background treatment. This analysis exam

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::19497fb7160409b832b42f0c1477c124
https://doi.org/10.1002/dmrr.646

Zobrazit plný text záznamu

Insulin Lispro Lowers Postprandial Glucose in Prepubertal Children With Diabetes

Autor: Morris R. Jenner, Stuart Brink, Martha Spencer, Kusiel Perlman, Hilary Kitson, Rocco L. Brunelle, Larry C. Deeb, John H. Holcombe, Sunita Zalani

Publikováno v: Pediatrics. 108:1175-1179

Objective. This study compared the glucose-lowering effect of insulin lispro, given before or after meals, with regular human insulin given before meals in prepubertal children with diabetes. Research Design and Methods. A 3-way crossover, open-label

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a18f200eb53cba3d18479b5473709044
https://doi.org/10.1542/peds.108.5.1175

Zobrazit plný text záznamu

A current review of olanzapine's safety in the geriatric patient: from pre-clinical pharmacology to clinical data

Autor: Donald P. Hay, Christian C. Felder, David O. Calligaro, Alan Breier, Martin Dossenbach, Mark Bernauer, John H. Holcombe, Christopher Kaiser, Bruce J. Kinon, John S. Kennedy, Mark B. Effron, Charles M. Beasley, Robert W. Baker, H. John Roth, George G. Nomikos, Leslie M. Schuh, Frank P. Bymaster

Publikováno v: International Journal of Geriatric Psychiatry. 16:S33-S61

Objective Olanzapine (OLZ) is unique among currently available antipsychotic medications in its antagonism of a range of receptor systems including dopamine, norepinephrine, serotonin, acetylcholine, and histamine. Olanzapine's mechanistic complexity

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::da6b1f51e15ece8e0fec94e3d36ca149
https://doi.org/10.1002/1099-1166(200112)16:1+<::aid-gps571>3.0.co

Zobrazit plný text záznamu

Effects of Exenatide and Lifestyle Modification on Body Weight and Glucose Tolerance in Obese Subjects With and Without Pre-Diabetes

Autor: Michael E. Trautmann, John H. Holcombe, Justin Northrup, Leslie Klaff, Kenneth Wilhelm, Sherwyn Schwartz, Julio Rosenstock

Publikováno v: Diabetes Care

OBJECTIVE To assess the effects of exenatide on body weight and glucose tolerance in nondiabetic obese subjects with normal or impaired glucose tolerance (IGT) or impaired fasting glucose (IFG). RESEARCH DESIGN AND METHODS Obese subjects (n = 152; ag

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4312c4643bc67df8df1c6a21a9b46667
http://europepmc.org/articles/PMC2875418

Zobrazit plný text záznamu

Changes in Free Insulin-Like Growth Factor-1 and Leptin Concentrations during Acute Metabolic Decompensation in Insulin Withdrawn Patients with Type 1 Diabetes1

Autor: David Silver, Timothy W. Jones, William V. Tamborlane, Najya Attia, Rubina A. Heptulla, Robert S. Sherwin, John H. Holcombe, Sonia Caprio

Publikováno v: The Journal of Clinical Endocrinology & Metabolism. 84:2324-2328

To determine the effect of acute insulin withdrawal and its subsequent replacement on components of the insulin-like growth factor (IGF)-1 binding protein system and on circulating leptin levels in patients with type 1 diabetes. Seventeen patients (a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::a991671bbb67ffbfdb93a54a475faf69
https://doi.org/10.1210/jcem.84.7.5861

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání